Prasugrel Versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study

Circulation

Volumn 134, Issue 21, 2016, Pages 1603-1612

  Motovska, Zuzana ^a   Hlinomaz, Ota ^b   Miklik, Roman ^c   Hromadka, Milan ^d   Varvarovsky, Ivo ^e   Dusek, Jaroslav ^f   Knot, Jiri ^a   Jarkovsky, Jiri ^g   Kala, Petr ^c   Rokyta, Richard ^d   Tousek, Frantisek ^h   Kramarikova, Petra ^b   Majtan, Bohumil ^i,j   Simek, Stanislav ^k   Branny, Marian ^l   Mrozek, Jan ^m   Cervinka, Pavel ⁿ   Ostransky, Jiri ^o   Widimsky, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Cardiology Centre AGEL Inc   (Czech Republic)

^f UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^g MASARYK UNIVERSITY   (Czech Republic)

^h Regional Hospital   (Czech Republic)

ⁱ Regional Hospital   (Czech Republic)

^j NA HOMOLCE HOSPITAL   (Czech Republic)

^k CHARLES UNIVERSITY   (Czech Republic)

^l Czech Republic Salvatella Ltd   (Czech Republic)

^m UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

ⁿ J E PURKINJE UNIVERSITY   (Czech Republic)

^o UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

more..

Author keywords

myocardial infarction; percutaneous coronary intervention; prasugrel hydrochloride; safety; ticagrelor; treatment outcome

Indexed keywords

ACETYLSALICYLIC ACID; PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY STENT; DIABETES MELLITUS; DOOR TO NEEDLE TIME; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART BUNDLE BRANCH BLOCK; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TIME; VESSEL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADENOSINE; ADULT; AGED; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE;

EID: 84996553455     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024823     Document Type: Article

References (27)

1. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D; Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310-318. doi: 10.1056/ NEJM199201303260506.
3. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:e123-e155. DOI: 10.1161/CIR.0000000000000404.
4. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.
5. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi: 10.1056/NEJMoa0706482.
6. Larmore C, Effron MB, Molife C, DeKoven M, Zhu Y, Lu J, Karkare S, Lieu HD, Lee WC, Vetrovec GW. "Real-world" comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv. 2016;88:535-544. doi: 10.1002/ccd.26279.
7. Motovska Z, Ondrakova M, Bednar F, Knot J, Ulman J, Maly M. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "real world" registry. Thromb Res. 2015;135:1093-1099. doi: 10.1016/j. thromres.2015.04.014.
8. Simeone JC, Molife C, Marrett E, Frech-Tamas F, Effron MB, Nordstrom BL, Zhu YE, Keller S, Murphy BR, Nair KV, Vetrovec GW, Page RL 2nd, McCollam PL. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. Am J Cardiovasc Drugs. 2015;15:337-350. doi: 10.1007/s40256-015-0147-y.
9. Danchin N, Lettino M, Zeymer U, Widimsky P, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Lopez Sendón J, Tousek P, Weidinger F, Weston CF, Zaman A, Andell P, Li J, Jukema JW; PIRAEUS Group. Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. Eur Heart J Cardiovasc Pharmacother. 2016;2:152-167. doi: 10.1093/ehjcvp/pvw003.
10. European Perspectives in Cardiology: Centres of Excellence: the Cardiocentre Prague, Czech Republic. Circulation. 2008;118(suppl):f13-f18.
11. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-731. doi: 10.1016/S0140-6736(09)60441-4.
12. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131-2141. doi: 10.1161 /CIRCULATIONAHA.109.927582.
13. Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Gabriel Steg P, James SK; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016;102:617-625. doi: 10.1136/heartjnl-2015-308963.
14. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51:2028-2033. doi: 10.1016/j.jacc.2008.04.002.
15. Silvain J, Bellemain-Appaix A, Barthélémy O, Beygui F, Collet JP, Montalescot G. Optimal use of thienopyridines in non-ST-elevation acute coronary syndrome following CURRENT-OASIS 7. Circ Cardiovasc Interv. 2011;4:95-103. doi: 10.1161/CIRCINTERVENTIONS. 109.910406.
16. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA, Kristensen SD, Rao SV, Verheugt FW, Widimsky P, Zeymer U, Collet JP. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32:1854-1864. doi: 10.1093/eurheartj/ehr204.
17. Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F. Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. Eur Heart J. 2013;34:1621-1629. doi: 10.1093/eurheartj/eht013.
18. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30. doi: 10.1093/eurheartj/ehm545.
19. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-2585. doi: 10.1161/ CIRCULATIONAHA.109.912550.
20. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323.
21. Montalescot G, Hof AW, Lapostolle F, Cantor WJ, Cequier A, Chettibi M, Collet JP, Goodman SG, Hammett CJ, Huber K, Janzon M, Lapostolle F, Lassen JF, Licour M, Merkely B, Salhi N, Silvain J, Storey RF, Ten Berg JM, Tsatsaris A, Zeymer U, Vicaut E, Hamm CW; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction, N Engl J Med. 2014;371:1016-1027.
22. Bernat I, Horak D, Stasek J, Mates M, Pesek J, Ostadal P, Hrabos V, Dusek J, Koza J, Sembera Z, Brtko M, Aschermann O, Smid M, Polansky P, Al Mawiri A, Vojacek J, Bis J, Costerousse O, Bertrand OF, Rokyta R. ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial. J Am Coll Cardiol. 2014;63:964-972. doi: 10.1016/j.jacc.2013.08.1651.
23. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemelä K, Steg PG, Bernat I, Xu Y, Cantor WJ, Overgaard CB, Naber CK, Cheema AN, Welsh RC, Bertrand OF, Avezum A, Bhindi R, Pancholy S, Rao SV, Natarajan MK, ten Berg JM, Shestakovska O, Gao P, Widimsky P, Dẑavík V; TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372:1389-1398. doi: 10.1056/ NEJMoa1415098.
24. Bednar F, Kroupa J, Ondrakova M, Osmancik P, Kopa M, Motovska Z. Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. J Thromb Thrombolysis. 2016;41:549-555. doi: 10.1007/s11239-015-1274-7.
25. Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Am J Cardiol. 2014;113:64-69. doi: 10.1016/j.amjcard.2013.09.019.
26. Klingenberg R, Heg D, Räber L, Carballo D, Nanchen D, Gencer B, Auer R, Jaguszewski M, Stähli BE, Jakob P, Templin C, Stefanini GG, Meier B, Vogt P, Roffi M, Maier W, Landmesser U, Rodondi N, Mach F, Windecker S, Jüni P, Lüscher TF, Matter CM. Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart. 2015;101:854-863. doi: 10.1136/heartjnl-2014-306925.
27. Pocock SJ, Gersh BJ. Do current clinical trials meet society's needs? A critical review of recent evidence. J Am Coll Cardiol. 2014;64:1615-1628. doi: 10.1016/j.jacc.2014.08.008.